Eribulin for advanced breast cancer: a drug evaluation
- PMID: 23593076
- PMCID: PMC3625759
- DOI: 10.4048/jbc.2013.16.1.12
Eribulin for advanced breast cancer: a drug evaluation
Abstract
Eribulin is a synthetic microtubule dynamics inhibitor that was developed from a marine natural product halichondrin B. It exhibited in vitro and in vivo activities against a wide number of malignancies. A number of advanced phase trials showed improved survival following eribulin treatment in pretreated advanced breast cancer patients. This review provides an overview of the background to the therapeutic use of eribulin in oncology, including its pharmacology, pharmacokinetics, clinical efficacy, safety, and potential economic factors.
Keywords: Breast neoplasms; Eribulin; Microtubule inhibitor.
Conflict of interest statement
The authors declare that they have no competing interests.
References
-
- Kingston DG. Taxol and its analogs. In: Cragg GM, Kingston DG, Newman DJ, editors. Anticancer Agents from Natural Products. 2nd ed. Boca Raton: CRC Press; 2005. pp. 123–135.
-
- Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665–667. - PubMed
-
- Hirata Y, Ohya S. Halichondrins: antitumor polyether macrolides from a marine sponge. Pure Appl Chem. 1986;58:701–710.
-
- Pettit GR, Herald CL, Boyd MR, Leet JE, Dufresne C, Doubek DL, et al. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem. 1991;34:3339–3340. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources